Left Atrial Appendage Closure Lacks Sufficient Evidence for Routine Use

Area of Science:

• Cardiology
• Medical Devices
• Clinical Trials

Background:

• Atrial fibrillation (AF) management often involves anticoagulation.
• Percutaneous left atrial appendage occlusion (pLAAO) is emerging as an alternative to oral anticoagulants.
• Non-vitamin K antagonist oral anticoagulants (NOACs) are standard therapy for stroke prevention in AF.

Purpose of the Study:

• To critically evaluate the current evidence supporting pLAAO as an alternative to NOACs for AF patients.
• To identify key limitations in existing clinical trial data for pLAAO.
• To assess the justification for the growing enthusiasm surrounding pLAAO.

Main Methods:

• Review and analysis of existing clinical trial data on pLAAO.
• Examination of primary efficacy endpoints and their components.
• Assessment of statistical power for detecting key clinical events.
• Evaluation of reported bleeding outcomes.

Main Results:

• Some trials utilized wide non-inferiority margins, potentially inflating perceived efficacy.
• Primary endpoints included factors not directly impacted by pLAAO, simplifying non-inferiority demonstration.
• Limited statistical power exists to reliably detect differences in ischemic stroke or systemic embolism rates.
• The reported bleeding advantage of pLAAO may be overstated.

Conclusions:

• The current evidence base does not fully support the widespread adoption of pLAAO over NOACs.
• Methodological limitations in trials necessitate cautious interpretation of pLAAO's benefits.
• Further robust clinical trials are required to definitively establish the role of pLAAO in AF management.